عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Indian Space Startup Launches Country's Second Privately Built Rocket

FILE PHOTO: Agnibaan SubOrbital Technological Demonstrator (SOrTeD), vehicle is seen at Agnikul's Launchpad at Satish Dhawan Space Center in Sriharikota, India, November 28, 2022. Agnikul Cosmos Private Limited/Handout via REUTERS
FILE PHOTO: Agnibaan SubOrbital Technological Demonstrator (SOrTeD), vehicle is seen at Agnikul's Launchpad at Satish Dhawan Space Center in Sriharikota, India, November 28, 2022. Agnikul Cosmos Private Limited/Handout via REUTERS
TT
TT

Indian Space Startup Launches Country's Second Privately Built Rocket

FILE PHOTO: Agnibaan SubOrbital Technological Demonstrator (SOrTeD), vehicle is seen at Agnikul's Launchpad at Satish Dhawan Space Center in Sriharikota, India, November 28, 2022. Agnikul Cosmos Private Limited/Handout via REUTERS
FILE PHOTO: Agnibaan SubOrbital Technological Demonstrator (SOrTeD), vehicle is seen at Agnikul's Launchpad at Satish Dhawan Space Center in Sriharikota, India, November 28, 2022. Agnikul Cosmos Private Limited/Handout via REUTERS

India's Agnikul Cosmos launched its Agnibaan rocket for the first time on Thursday, powered by the only Indian rocket engine to use both gas and liquid fuel in the country's second flight of a privately built rocket.
The Agnibaan's first flight had been called off four times in the last two months because of technical issues. The most recent cancellation was Tuesday, when launch was aborted five seconds before lift-off, Reuters reported.
The South Asian nation's space agency, the Indian Space Research Organization (ISRO), has not successfully flown a rocket with a so-called "semi-cryogenic" engine.
"A major milestone, as the first-ever controlled flight of a semi-cryogenic liquid engine realized through additive manufacturing," ISRO said on social media platform X.
Agnibaan is a customizable, two-stage launch vehicle that can carry a payload of up to 300 kg (661 lb) into orbit of about 700 kilometers (435 miles).
The suborbital flight on Thursday was meant to test the new engine and 3D-printed parts; the company did not immediately say how long the test lasted or what altitude the rocket reached.
Pawan K Goenka, chairman of space regulator Indian National Space Promotion and Authorisation Center (IN-SPACe), also hailed the "historic moment". The Indian Space Association (ISpA) said the launch would "bolster global confidence" in the country's private space industry.
India Prime Minister Narendra Modi has been pushing for the privatization and commercialization of the country's space sector in the last few years.
India's first privately developed rocket, from the company Skyroot, flew in 2022.
Agnikul, whose name is derived from the Hindi and Sanskrit work for fire, was founded in 2017 and runs India's first private launchpad and mission control center. All other launchpads are operated by ISRO.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”